Drug intelligence / Profile preview

RC-0315

Development stage: Unknown
Lead developer: Remedy Cell
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intrabronchial

Overview

RC-0315 is a cell-free, mesenchymal stem cell (MSC)-derived secretome therapeutic being developed by Remedy Cell for the treatment of idiopathic pulmonary fibrosis (IPF). Unlike traditional cell therapies, RC-0315 utilizes the bioactive factors (secretome) secreted by MSCs rather than the cells themselves, potentially offering a safer and more scalable approach to regenerative medicine. The manufacturing process, conducted in collaboration with PluriCDMO, utilizes a proprietary 3D cell expansion system to produce clinical-grade batches. The candidate is currently advancing toward Phase 1b clinical development.

Beyond the preview

Go deeper on RC-0315.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RC-0315.

Explore the full profile